Safety, Tolerability and Performance of SmartMatrix Dermal Replacement Scaffold

Inclusion Criteria: * Male or female, at least 18 years of age * Suspected or histologically proven BCC or SCC * Suspected or histologically proven BCC or SCC ≥1cm ≤3cm in diameter on either leg * Expected defect following surgery ≥3cm, ≤6cm in diameter * Patient or authorised representative able to comprehend and sign the Informed Consent prior to enrolment in the study Exclusion Criteria: * Aged \<18 years of age * Pregnant or lactating females * Skin lesion \>4cm in diameter or size that will result in post-surgical defect \>6cm in diameter * Lesion located over joint, i.e. ankle or knee * Patient who are smokers * Diabetic patients * Patients diagnosed with peripheral vascular disease or venous stasis * Patients receiving regular systemic steroids * Patients who are immuno-compromised (either acquired or congenital) * Patients with a known coagulopathy (either acquired or congenital) but not including patients on aspirin or other anti-platelet therapy * Patients who have received radiotherapy treatment to the area about to be treated with Smart Matrix * Concurrent participation in another experimental intervention or drug study * Unwilling or unable to provide informed consent